Olivier Huillard

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

Olivier Huillard, Olivier Mir, Michaël Peyromaure et al. · British Journal of Cancer · 2013 · 224 citations · Full text

Medicine, Oncology, Pharmacology +15

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice

A. Berdelou, Isabelle Borget, Yann Godbert et al. · Thyroid · 2017 · 123 citations

Medicine, Oncology, Pharmacotherapy +11

Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy ,

Clara Vazeille, Anne Jouinot, Jean-Philippe Durand et al. · American Journal of Clinical Nutrition · 2017 · 98 citations

Medicine, Oncology, Chemotherapy +9